Google
NSRX — NASUS PHARMA LTD. (Healthcare >> Drug Manufacturers - General)
NSRX FAQ
What is NSRX's ROE?
NASUS PHARMA LTD. reports a Return on Equity (ROE) of -211.56%.
What is NSRX's dividend yield?
NASUS PHARMA LTD. offers a dividend yield of 0.00%.
What is NSRX's Deepscope Quality Score?
Deepscope rates NSRX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NSRX?
Deepscope's AI Timing Score for NSRX is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NSRX belong to?
NASUS PHARMA LTD. is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE MKT exchange.
|
USD 2.93
Price
-0.31
(-9.57%)
Day Change
|
|
|---|
NSRX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
36% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.93 |
| PBV / Sector |
9.54 / 2.84
|
| Earning Per Share | -0.65 |
| PE / Sector |
N/A / 24.53
|
| PEG or PE/Growth / Sector |
N/A / 0.08
|
| Average 1M Daily Value |
0.15 M
GREAT
|
| Average 1W Daily Value |
0.15 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:51 |
| Symbol | NSRX |
| Name | NASUS PHARMA LTD. |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE MKT |
| Listed Shares | 11.71 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 26.42 / 241,254.65 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Yigal Alon 65, Tel Aviv, Israel, 6744317
Phone: 972 3 573 6632
Website: https://www.nasuspharma.com
Description: Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
